NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned an average recommendation of “Hold” from the twelve analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.8571.

NEO has been the subject of several recent research reports. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. UBS Group restated a “hold” rating on shares of NeoGenomics in a research report on Wednesday, February 18th. Needham & Company LLC lifted their target price on shares of NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. TD Cowen boosted their target price on shares of NeoGenomics from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, Piper Sandler increased their price target on shares of NeoGenomics from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, February 24th.

Institutional Investors Weigh In On NeoGenomics

Hedge funds have recently modified their holdings of the company. Aster Capital Management DIFC Ltd raised its holdings in NeoGenomics by 42.5% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after purchasing an additional 997 shares during the period. First Horizon Corp lifted its holdings in NeoGenomics by 52.6% during the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 865 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of NeoGenomics in the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd grew its position in shares of NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 1,556 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in shares of NeoGenomics during the fourth quarter worth about $39,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Price Performance

NASDAQ:NEO opened at $10.90 on Wednesday. NeoGenomics has a one year low of $4.72 and a one year high of $13.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.06 and a current ratio of 4.42. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -14.16 and a beta of 1.82. The firm’s fifty day moving average is $8.70 and its two-hundred day moving average is $10.30.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The business had revenue of $186.67 million during the quarter, compared to analyst estimates of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company’s revenue was up 11.3% compared to the same quarter last year. Research analysts expect that NeoGenomics will post -0.15 EPS for the current year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.